Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin for Nocturia in Men With BPH
NCT00793819Phase 2Completed
- Sponsor
- Watson Pharmaceuticals
- Start
- Jan 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nocturia and benign prostatic hyperplasia (BPH) comparing Silodosin with Placebo (2 arms). Primary endpoint: Change in Nocturia Episodes at 12 weeks. Started Jan 2009; status: completed.
02
Drugs
silodosin
03
Conditions
nocturiabenign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00793819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793819.